High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events - Insights from phenotype and genotype characterization

Vascular Pharmacology

Volumn 77, Issue , 2016, Pages 60-68

  Leiherer, Andreas ^a,c,d   Muendlein, Axel ^a,c   Kinz, Elena ^a,c   Vonbank, Alexander ^a,b   Rein, Philipp ^a,b   Fraunberger, Peter ^c,d   Malin, Cornelia ^a,b   Saely, Christoph H ^a,b,c   Drexel, Heinz ^a,b,c,e  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b Academic Teaching Hospital Feldkirch   (Austria)

^c PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^d Medical Central Laboratory   (Austria)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Adipokine; Cardio Metabo Chip; Chemerin; Coronary artery disease; Renal dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMERIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; SIGNAL PEPTIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHROMOSOME 15Q; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETIC PATIENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CHROMOSOME 15; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DISEASE COURSE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; KAPLAN MEIER METHOD; MORTALITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGED; CHEMOKINES; CHROMOSOMES, HUMAN, PAIR 15; COHORT STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84958045434     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.010     Document Type: Article

References (62)

1. Sell H., Divoux A., Poitou C., Basdevant A., Bouillot J.L., Bedossa P., Tordjman J., Eckel J., Clement K. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 2010, 95:2892-2896.
2. Wittamer V., Franssen J.D., Vulcano M., Mirjolet J.F., Le Poul E., Migeotte I., Brezillon S., Tyldesley R., Blanpain C., Detheux M., Mantovani A., Sozzani S., Vassart G., Parmentier M., Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 2003, 198:977-985.
3. Becker M., Rabe K., Lebherz C., Zugwurst J., Goke B., Parhofer K.G., Lehrke M., Broedl U.C. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 2010, 59:2898-2903.
4. Bozaoglu K., Curran J.E., Stocker C.J., Zaibi M.S., Segal D., Konstantopoulos N., Morrison S., Carless M., Dyer T.D., Cole S.A., Goring H.H., Moses E.K., Walder K., Cawthorne M.A., Blangero J., Jowett J.B. Chemerin, a novel adipokine in the regulation of angiogenesis. J. Clin. Endocrinol. Metab. 2010, 95:2476-2485.
5. Banas M., Zabieglo K., Kasetty G., Kapinska-Mrowiecka M., Borowczyk J., Drukala J., Murzyn K., Zabel B.A., Butcher E.C., Schroeder J.M., Schmidtchen A., Cichy J. Chemerin is an antimicrobial agent in human epidermis. PLoS One 2013, 8:e58709.
6. Skrzeczynska-Moncznik J., Wawro K., Stefanska A., Oleszycka E., Kulig P., Zabel B.A., Sulkowski M., Kapinska-Mrowiecka M., Czubak-Macugowska M., Butcher E.C., Cichy J. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem. Biophys. Res. Commun. 2009, 380:323-327.
7. Zabel B.A., Silverio A.M., Butcher E.C. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol. 2005, 174:244-251.
8. Watts S.W., Dorrance A.M., Penfold M.E., Rourke J.L., Sinal C.J., Seitz B., Sullivan T.J., Charvat T.T., Thompson J.M., Burnett R., Fink G.D. Chemerin connects fat to arterial contraction. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1320-1328.
9. Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., Collier G., Walder K., Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148:4687-4694.
10. Goralski K.B., McCarthy T.C., Hanniman E.A., Zabel B.A., Butcher E.C., Parlee S.D., Muruganandan S., Sinal C.J. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 2007, 282:28175-28188.
11. Albanesi C., Scarponi C., Pallotta S., Daniele R., Bosisio D., Madonna S., Fortugno P., Gonzalvo-Feo S., Franssen J.D., Parmentier M., De Pita O., Girolomoni G., Sozzani S. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J. Exp. Med. 2009, 206:249-258.
12. Weigert J., Obermeier F., Neumeier M., Wanninger J., Filarsky M., Bauer S., Aslanidis C., Rogler G., Ott C., Schaffler A., Scholmerich J., Buechler C. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm. Bowel Dis. 2010, 16:630-637.
13. Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R., Farkas S., Scherer M.N., Schaffler A., Aslanidis C., Scholmerich J., Buechler C. Systemic chemerin is related to inflammation rather than obesity in Type 2 diabetes. Clin. Endocrinol. (Oxf) 2010, 72:342-348.
14. Landgraf K., Friebe D., Ullrich T., Kratzsch J., Dittrich K., Herberth G., Adams V., Kiess W., Erbs S., Korner A. Chemerin as a mediator between obesity and vascular inflammation in children. J. Clin. Endocrinol. Metab. 2012, 97:E556-E564.
15. Li Y., Shi B., Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One 2014, 9:e113915.
16. Müssig K., Staiger H., Machicao F., Thamer C., Machann J., Schick F., Claussen C.D., Stefan N., Fritsche A., Haring H.U. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study. Metabolism 2009, 58:519-524.
17. Yan Q., Zhang Y., Hong J., Gu W., Dai M., Shi J., Zhai Y., Wang W., Li X., Ning G. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 2012, 41:281-288.
18. Xiaotao L., Xiaoxia Z., Yue X., Liye W. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron. Artery Dis. 2012, 23:412-416.
19. Hah Y.J., Kim N.K., Kim M.K., Kim H.S., Hur S.H., Yoon H.J., Kim Y.N., Park K.G. Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in Korean patients with coronary artery disease. Diabetes Metab. J. 2011, 35:248-254.
20. Lehrke M., Becker A., Greif M., Stark R., Laubender R.P., von Ziegler F., Lebherz C., Tittus J., Reiser M., Becker C., Goke B., Leber A.W., Parhofer K.G., Broedl U.C. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol. 2009, 161:339-344.
21. Mattu H.S., Randeva H.S. Role of adipokines in cardiovascular disease. J. Endocrinol. 2013, 216:T17-T36.
22. Pfau D., Bachmann A., Lossner U., Kratzsch J., Bluher M., Stumvoll M., Fasshauer M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010, 33:171-173.
23. Yamamoto T., Qureshi A.R., Anderstam B., Heimburger O., Barany P., Lindholm B., Stenvinkel P., Axelsson J. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol. Dial. Transplant. 2010, 25:4017-4023.
24. Rutkowski P., Sledzinski T., Zielinska H., Lizakowski S., Goyke E., Szrok-Wojtkiewicz S., Swierczynski J., Rutkowski B. Decrease of serum chemerin concentration in patients with end stage renal disease after successful kidney transplantation. Regul. Pept. 2012, 173:55-59.
25. Rein P., Vonbank A., Saely C.H., Beer S., Jankovic V., Boehnel C., Breuss J., Risch L., Fraunberger P., Drexel H. Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without Type 2 diabetes mellitus and stable or suspected coronary artery disease. Am. J. Cardiol. 2011, 107:1144-1148.
26. Rein P., Saely C.H., Muendlein A., Vonbank A., Drexel H. Serial decline of kidney function as a novel biomarker for the progression of atherothrombotic disease. Atherosclerosis 2010, 211:348-352.
27. Hu W., Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in Type 2 diabetic patients. Diabetes Res. Clin. Pract. 2011, 91:159-163.
28. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol. Dial. Transplant. 2008, 23:3041-3046.
29. Bobbert T., Schwarz F., Fischer-Rosinsky A., Maurer L., Mohlig M., Pfeiffer A.F., Mai K., Spranger J. Chemerin and prediction of Diabetes mellitus Type 2. Clin. Endocrinol. (Oxf) 2015, 10.1111/cen.12707.
30. Hu W., Yu Q., Zhang J., Liu D. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation 2012, 35:1287-1293.
31. Muruganandan S., Parlee S.D., Rourke J.L., Ernst M.C., Goralski K.B., Sinal C.J. Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis. J. Biol. Chem. 2011, 286:23982-23995.
32. Dobrian A.D. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor. Vascul. Pharmacol. 2006, 45:36-45.
33. Stejskal D., Karpisek M., Hanulova Z., Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-pilot study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2008, 152:217-221.
34. Bakris G.L., Hart P., Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006, 70:1905-1913.
35. Kim H.M., Lee B.W., Song Y.M., Kim W.J., Chang H.J., Choi D.H., Yu H.T., Kang E., Cha B.S., Lee H.C. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with Type 2 diabetes mellitus. Cardiovasc. Diabetol. 2012, 11:84.
36. Ji Q., Lin Y., Liang Z., Yu K., Liu Y., Fang Z., Liu L., Shi Y., Zeng Q., Chang C., Chai M., Zhou Y. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovasc. Diabetol. 2014, 13:145.
37. Kadoglou N.P., Tahmatzidis D.K., Giannakoulas C., Kapelouzou A., Gkontopoulos A., Parissis J., Lampropoulos S., Kottas G. Serum levels of novel adipokines, omentin-and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. J. Cardiovasc. Med. (Hagerstown) 2015, 16:341-346.
38. Tönjes A., Scholz M., Breitfeld J., Marzi C., Grallert H., Gross A., Ladenvall C., Schleinitz D., Krause K., Kirsten H., Laurila E., Kriebel J., Thorand B., Rathmann W., Groop L., Prokopenko I., Isomaa B., Beutner F., Kratzsch J., Thiery J., Fasshauer M., Kloting N., Gieger C., Bluher M., Stumvoll M., Kovacs P. Genome wide meta-analysis highlights the role of genetic variation in RARRES2 in the regulation of circulating serum chemerin. PLoS Genet. 2014, 10:e1004854.
39. Rask-Andersen M., Jacobsson J.A., Moschonis G., Ek A.E., Chrousos G.P., Marcus C., Manios Y., Fredriksson R., Schioth H.B. The MAP2K5-linked SNP rs2241423 is associated with BMI and obesity in two cohorts of Swedish and Greek children. BMC Med. Genet. 2012, 13:36.
40. Wen W., Cho Y.S., Zheng W., Dorajoo R., Kato N., Qi L., Chen C.H., Delahanty R.J., Okada Y., Tabara Y., Gu D., Zhu D., Haiman C.A., Mo Z., Gao Y.T., Saw S.M., Go M.J., Takeuchi F., Chang L.C., Kokubo Y., Liang J., Hao M., Le Marchand L., Zhang Y., Hu Y., Wong T.Y., Long J., Han B.G., Kubo M., Yamamoto K., Su M.H., Miki T., Henderson B.E., Song H., Tan A., He J., Ng D.P., Cai Q., Tsunoda T., Tsai F.J., Iwai N., Chen G.K., Shi J., Xu J., Sim X., Xiang Y.B., Maeda S., Ong R.T., Li C., Nakamura Y., Aung T., Kamatani N., Liu J.J., Lu W., Yokota M., Seielstad M., Fann C.S., Wu J.Y., Lee J.Y., Hu F.B., Tanaka T., Tai E.S., Shu X.O. Meta-analysis identifies common variants associated with body mass index in east Asians. Nat. Genet. 2012, 44:307-311.
41. Chen L., Hou J., Ye L., Chen Y., Cui J., Tian W., Li C., Liu L. MicroRNA-143 regulates adipogenesis by modulating the MAP2K5-ERK5 signaling. Sci. Rep. 2014, 4:3819.
42. Tagawa K., Taya C., Hayashi Y., Nakagawa M., Ono Y., Fukuda R., Karasuyama H., Toyama-Sorimachi N., Katsui Y., Hata S., Ishiura S., Nonaka I., Seyama Y., Arahata K., Yonekawa H., Sorimachi H., Suzuki K. Myopathy phenotype of transgenic mice expressing active site-mutated inactive p94 skeletal muscle-specific calpain, the gene product responsible for limb girdle muscular dystrophy Type 2A. Hum. Mol. Genet. 2000, 9:1393-1402.
43. Walder K., McMillan J., Lapsys N., Kriketos A., Trevaskis J., Civitarese A., Southon A., Zimmet P., Collier G. Calpain 3 gene expression in skeletal muscle is associated with body fat content and measures of insulin resistance. Int. J. Obes. Relat. Metab. Disord. 2002, 26:442-449.
44. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
45. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
46. Molchadsky A., Ezra O., Amendola P.G., Krantz D., Kogan-Sakin I., Buganim Y., Rivlin N., Goldfinger N., Folgiero V., Falcioni R., Sarig R., Rotter V. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ. 2013, 20:774-783.
47. Scanlon P.J., Faxon D.P., Audet A.M., Carabello B., Dehmer G.J., Eagle K.A., Legako R.D., Leon D.F., Murray J.A., Nissen S.E., Pepine C.J., Watson R.M., Ritchie J.L., Gibbons R.J., Cheitlin M.D., Gardner T.J., Garson A., Russell R.O., Ryan T.J., Smith S.C. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J. Am. Coll. Cardiol. 1999, 33:1756-1824.
48. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998, 15:539-553.
49. World Health Organization Obesity and overweight. WHO Fact Sheet No. 311 2013, (http://www.who.int).
50. Expert Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
51. Drexel H., Amann F.W., Beran J., Rentsch K., Candinas R., Muntwyler J., Luethy A., Gasser T., Follath F. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994, 90:2230-2235.
52. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., Hoefle G., Drexel H. Lipoprotein(a), Type 2 diabetes and vascular risk in coronary patients. Eur. J. Clin. Invest. 2006, 36:91-97.
53. Rule A.D., Larson T.S., Bergstralh E.J., Slezak J.M., Jacobsen S.J., Cosio F.G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann. Intern. Med. 2004, 141:929-937.
54. Risch L., Saely C.H., Neyer U., Hoefle G., Gouya G., Zerlauth M., Risch G.M., Risch M., Drexel H. Prevalence of decreased glomerular filtration rate in patients seeking non-nephrological medical care-an evaluation using IDMS-traceable creatinine based MDRD as well as Mayo Clinic quadratic equation estimates. Clin. Chim. Acta 2007, 378:71-77.
55. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-S266.
56. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
57. Voight B.F., Kang H.M., Ding J., Palmer C.D., Sidore C., Chines P.S., Burtt N.P., Fuchsberger C., Li Y., Erdmann J., Frayling T.M., Heid I.M., Jackson A.U., Johnson T., Kilpelainen T.O., Lindgren C.M., Morris A.P., Prokopenko I., Randall J.C., Saxena R., Soranzo N., Speliotes E.K., Teslovich T.M., Wheeler E., Maguire J., Parkin M., Potter S., Rayner N.W., Robertson N., Stirrups K., Winckler W., Sanna S., Mulas A., Nagaraja R., Cucca F., Barroso I., Deloukas P., Loos R.J., Kathiresan S., Munroe P.B., Newton-Cheh C., Pfeufer A., Samani N.J., Schunkert H., Hirschhorn J.N., Altshuler D., McCarthy M.I., Abecasis G.R., Boehnke M. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet. 2012, 8:e1002793.
58. International Hapmap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320.
59. de Bakker P.I., Yelensky R., Pe'er I., Gabriel S.B., Daly M.J., Altshuler D. Efficiency and power in genetic association studies. Nat. Genet. 2005, 37:1217-1223.
60. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
61. Muendlein A., Stark N., Rein P., Saely C.H., Geller-Rhomberg S., Geiger K., Vonbank A., Drexel H. Are AHSG polymorphisms directly associated with coronary atherosclerosis?. Clin. Chim. Acta 2012, 413:287-290.
62. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.